The NAVIX™ Access Device is cleared for pancreatic pseudocyst drainage in the US and has CE Mark approval.
The AXIOS™ Stent and Delivery System, the first stent designed for endoscopic ultrasound-guided translumenal therapy, has CE Mark approval.
If you are interested in bringing our products to your facility, please contact us.
Xlumena, Inc. is currently enrolling subjects in its AXIOS Stent and Delivery System IDE (Investigational Device Exemption) Study. The study is a prospective, multi-center, non-randomized study to evaluate the safety and effectiveness of the AXIOS Stent and Delivery System to drain a pancreatic pseudocyst. Twenty-four subjects will be enrolled at up to 10 investigational sites in the United States, Japan and/or the European Community. For more information go to: http://www.clinicaltrials.gov/ct2/show/NCT01419769.
We're thinking advanced therapy.
At Xlumena, we focus on interventional innovation, the practice of listening to physicians, leveraging their expertise, and being inspired by their vision. That inspiration, along with our design capabilities and resources, guides the development of our products. Our devices and tools will extend the reach of those who use them and take interventional endoscopy to a new, innovative and therapeutic level.
About Xlumena
Xlumena is the leader in the development of image-guided therapeutic endoscopy products specializing in advanced implants and devices that address multiple markets. Collaborating with top physicians in the field, Xlumena focuses on technology that advances therapy to the next level. These innovations may enable numerous translumenal therapeutic procedures, helping transform complex surgeries into outpatient events.
Join Our Collaborative Approach to New Product Development
If you are a physician interested in joining our Advanced Translumenal Therapy User Group, please contact our development team
COMPANY PROFILE
